Organisation paid for research Program year 2025 Source: CMS Open Payments

Trinity Health

Neither a doctor nor a teaching hospital

Research payments

$649,232

288 payments

Through program year 2025, Trinity Health is reported as receiving $649,232 in research payments, across 288 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$83,178	38
2024	Research	$194,747	73
2023	Research	$42,389	28
2022	Research	$33,968	34
2021	Research	$134,436	41
2020	Research	$88,493	28
2019	Research	$72,022	46

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $130,874 59 payments
Sun Pharmaceutical Industries Inc. $104,829 80 payments
Daiichi Sankyo Company LTD $92,532 12 payments
Daiichi Sankyo Inc. $84,000 50 payments
Octapharma USA, Inc. $75,244 2 payments
Pfizer Inc. $49,056 45 payments
AbbVie, Inc. $38,941 11 payments
Eli Lilly and Company $28,759 9 payments
American Regent $18,966 8 payments
Boston Scientific Corporation $7,447 2 payments

Studies the money was for Research payments · program years 2019–2025

Ds7011-107 $176,532 62 payments
Gam10-10 $75,244 2 payments
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $72,624 42 payments
A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $58,570 37 payments
A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $47,210 13 payments
Phase 3B4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor TNF Inhibitor in Subjects With Rheumatoid Arthritis $39,779 43 payments
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) $28,927 9 payments
A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $25,094 9 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $21,208 6 payments
Heart_FID $18,966 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.